A Study of Single Doses to Evaluate the Safety, Tolerability, Pharmacokinetics and Target Engagement of Nebulised GSK3008348 in Idiopathic Pulmonary Fibrosis Patients, Using Positron Emission Tomography (PET) Imaging
Phase of Trial: Phase I
Latest Information Update: 11 Jun 2018
At a glance
- Drugs GSK 3008348 (Primary) ; GSK 2634673F
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors GlaxoSmithKline
- 07 Jun 2018 Planned End Date changed from 28 Mar 2019 to 9 May 2019.
- 07 Jun 2018 Planned primary completion date changed from 28 Mar 2019 to 9 May 2019.
- 02 Apr 2018 Planned End Date changed from 22 Feb 2019 to 28 Mar 2019.